Batimastat is a broad spectrum inhibitor of matrix metalloproteinases (MMP), with IC50 values of 1-5 nM for all MMPs tested, including MMP-1, -2, -3, -7, -9, -13, and -14. It also potently inhibits TNFα-converting enzyme (IC50 = 14.9 nM). Because of its action on MMPs, batimastat has anti-proliferative, anti-invasive, and anti-metastatic actions that are relevant, in particular, to cancer. Batimastat less effectively inhibits the processing of the low affinity IgE receptor CD23 (IC50 = 100 nM).
